Epidemiology and Infection

Self-reported patient history to assess hepatitis B virus serological status during a large screening campaign

A. Boyd1, J. Gozlan2,3, F. Carrat4,5, H. Rougier6, P.-M. Girard5,6, K. Lacombe5,6 and J. Bottero1,6

Abstract

When assessing hepatitis B virus (HBV) status in clinical settings, it is unclear whether self-reports on vaccination history and previous HBV-test results have any diagnostic capacity. Of 3997 participants in a multi-centre HBV-screening study in Paris, France, 1090 were asked questions on their last HBV-test result and vaccination history. Discordance between self-reported history compared with infection status (determined by serology) was calculated for participants claiming ‘negative’, ‘effective vaccine’, ‘past infection’, or ‘chronic infection’ HBV-status. Serological testing revealed that 320 (29.4%) were non-immunised, 576 (52.8%) were vaccinated, 173 (15.9%) had resolved the infection and 21 (1.9%) were hepatitis B surface antigen positive. In total 208/426 (48.8%) participants with a self-reported history of ‘negative’ infection had a discordant serological result, in whom 128 (61.5%) were vaccinated and 74 (35.6%) had resolved infections. A total of 153/599 (25.5%) participants self-reporting ‘effective vaccine’ had a discordant serological result, in whom 100 (65.4%) were non-immunised and 50 (32.7%) were resolved infections. Discordance for declaring ‘past’ or ‘chronic infection’ occurred in 9/55 (16.4%) and 3/10 (30.0%) individuals, respectively. In conclusion, self-reported HBV-status based on participant history is partially inadequate for determining serological HBV-status, especially between negative/vaccinated individuals. More adapted patient education about HBV-status might be helpful for certain key populations.

Introduction

Approximately 18.5 million persons are infected with hepatitis B virus (HBV) in Europe [1]. Epidemiological evidence suggests that roughly three-quarters of them are unaware of their infection [2], which, if left poorly managed or untreated during active phases, could lead to further progression of liver disease, hepatocellular carcinoma and death [3, 4]. Vaccine coverage rates are also low in many countries across Europe [5], leaving a considerable proportion of individuals at risk of acquiring HBV. Consequently, there is an urgent need to identify infected persons requiring appropriate care and to determine those eligible for HBV vaccination. Several HBV screening guidelines have been proposed and implemented over recent years and recommend an approach targeting populations at-risk of infection [6]. Routine screening has been largely successful in identifying infected individuals at sexually-transmitted disease (STD) clinics and among immigrant populations from moderate to high HBV-endemic regions, sex-workers and intravenous-drug users (IDUs) [7-9]. Furthermore, testing has been simplified with the development of rapid point-of-care technology, which has provided a quick and convenient means to accurately test for infection and link patients to care [10]. Nevertheless, in France, there were a total of 43 18 664 tests given for 33 962 HBsAg-positive cases in 2016 [11] and a large number of these tests could be regarded as unnecessary [7]. Among individuals already tested for HBV, it is uncertain whether repeat screening could provide any public health benefit, especially if the individual is considered no longer at risk of infection [12, 13]. HBV testing could be reduced by basing the need to test on patient history, yet this would depend on the reliability of patient recollection. For example, self-reports of vaccinated status have demonstrated poor concordance compared with serological results in IDUs [14, 15], individuals testing in STD clinics [16] and men who have sex with men (MSM) [17].

In one study conducted in Paris, France, a false understanding of vaccinated status was more frequently observed in individuals with previous HBV testing [18]. Reported vaccination status alone is unlikely to assist in determining testing eligibility.
Combining patients’ understanding of their previous HBV test with HBV vaccination history could help more accurately assess patients’ HBV status and thus need to test. However, very few studies have evaluated this approach. In the present study, we aimed to explore the validity of individual self-reported HBV-status obtained from questions related to participants’ history (i.e. vaccinated status and previous HBV test result) compared with serological results during a mass screening campaign in Paris, France.

Methods

Study design and participants

The OPTISCREEN-B program is a multicentre cross-sectional study, whose primary objective was to evaluate several rapid tests for chronic HBV [10]. Briefly, ten healthcare centres were selected to represent those whose objectives included screening, prevention and/or vaccination of diverse populations. More specifically, these centres provided one of the following services: free and anonymous sexually transmitted disease (STD) testing (Consultation de dépistage anonyme et gratuite (CDAG) Belleville, CDAG Figuer, CDAG St Antoine); testing for the general population (Centre d'examen de santé de la Caisse Primaire d'Assurance Maladie (CPAM), Consultation Voyage St Antoine), immigrants and persons with low socio-economic status (Centre de Santé rue au Maire, Médecins du Monde, Policlinique St Antoine, Croix-Rouge Moulin Joly), or incarcerated individuals (Unité de consultations et de soins ambulatoires (UCSA)). All centres were required to be in the Paris metropolitan region so that HBV-infected patients could be referred to a single hospital (Saint-Antoine Hospital, Paris) for subsequent care.

The target screening population was persons potentially eligible for HBV-testing. Since one major factor steering the decision to test in practice is complete certainty of prior HBV-infection or vaccination status, participants with a confirmed HBsAg-positive, anti-HBsAg antibody-positive, or anti-HBcAb antibody-positive test (requiring proof of result) were not included. This means that participants were still eligible if they declared having a previous test or vaccination but were unable to provide proof. Participants whose result was negative for all three HBV serological markers ≥6 months prior were also eligible. Important: no participant was excluded based on nationality, legal status or access to government-provided healthcare.

From September 2010 to August 2011, volunteers were asked to participate during their regular consultation if ≥18-years-old and available for further contact. For the present study, only individuals claiming previous HBV testing were included. All participants provided written informed consent in their native language and the protocol was approved by the Hôtel-Dieu Hospital Ethics Committee (Paris, France) in accordance with the Helsinki Declaration.

HBV serological battery and definition of HBV-disease status

Full screening procedures have been detailed elsewhere [10]. A complete HBV serological battery was performed for all participants and included HBsAg, anti-HBs antibodies, hepatitis B ‘e’ antigen (HBeAg), anti-hepatitis B ‘e’ (HBe) antibodies and anti-HBc antibodies (MONOLISA AgHBs Ultra, anti-HBs plus, anti-hepatitis B core antibody-anti-HBc-plus, BIORAD, Hercules, USA). For this study, HBV-disease status was classified using serological results as follows: non-immunised, resolved infection, vaccinated and HBsAg-positive (Table 1).

Assessing HBV-related participant history

Participants were asked whether they had a previous HBV-test and could answer ‘yes’, ‘no’ or ‘do not know or remember’. Individuals responding ‘yes’ were then questioned on whether they obtained a test result and if so, which of the following best described their result: negative (‘no past exposure’), ‘meant that your vaccine worked’, ‘meant that your infection was cured’, ‘meant that you have chronic infection’, or ‘do not know or remember’. Tested participants were also asked to specify the reason for testing, choosing one of the following: ‘as part of a normal health check-up’, ‘during blood donation’, ‘before getting vaccinated for hepatitis B’, ‘problems from liver tests’, or ‘because I have a transmission risk-factor’.

Participants were also asked whether they had been vaccinated against HBV infection and could answer ‘yes’, ‘no’ or ‘do not know or remember’. Individuals responding ‘yes’ were then questioned on the age at which they were vaccinated (either continuous or specified as during ‘birth’, ‘adolescence’, or ‘adult hood’), the number of vaccinations they received and whether they verified protective antibodies with a serological test any time after vaccination.

Statistical analysis

Based on participants’ answers to questions on vaccination history and previous HBV-test result, we constructed four self-reported HBV-status groups: (i) negative, (ii) effective vaccine, (iii) past infection and (iv) chronic infection. Any individual who claimed HBV vaccination prior to participation (responding ‘yes’ to the question on HBV vaccination) was classified as belonging to the ‘effective vaccine’ group. All other individuals were then categorised in groups corresponding to their previous HBV-test result. We compared participant self-reported vs. serological HBV-infection status using unweighted 𝜅.

Using serological testing as the gold standard, discordance was defined as the conditional probability of not having a true disease status given the participant’s self-report (1-sensitivity). Risk-factors for discordance were evaluated for each self-report group, provided that there were a sufficient number of participants (n > 100). Unadjusted odds ratios (OR) and their 95% confidence intervals (CI) were calculated from random-effects logistic regression models accounting for within-centre correlation (due to centre-specific experience with healthcare services) [19].

All statistical analyses were performed using STATA (v12.1, College Station, TX, USA) statistical software and significance was determined using a P-value <0.05.
### Table 1. Definition of HBV infection status

| HBV infection status | HBsAg | anti-HBc Ab | anti-HBs Ab |
|----------------------|-------|------------|------------|
| Non-immunised        | –     | –          | –          |
| Vaccinated           | –     | +          | +          |
| Resolved infection*  | –     | +          | +/–        |
| HBsAg-positive       | +/–   | –          | +/–        |

Ab, antibodies; HBc, hepatitis B core; HBs, hepatitis B surface; HBsAg, HBs antigen; HBV, hepatitis B virus.

*Individuals with isolated anti-HBc antibody positive serology (n = 37) were regrouped with those having resolved infection in the analysis.

### Results

#### Description of the study population

A total of 3997 individuals participated in the initial HBV screening study. Of them, 2907 were not included because they had incomplete or unavailable serological results (n = 68), did not have a previous HBV-test (n = 2120), were unsure of having an HBV test (n = 610), or did not obtain their last HBV-test result (n = 109). In total, 1090 participants were included in the analysis. Included individuals were more likely to have a risk factor for HBV transmission or to come from a country of intermediate/high HBV prevalence compared with those non-included (Supplementary Table 1).

Table 2 describes patient characteristics in function of self-reported HBV-status. Participants reporting past infection and the effective vaccine had significantly older and younger median ages, respectively, when compared with other groups (P < 0.001). As expected, many of the factors related to regions of moderate-to-high HBV-endemicity were significantly more frequent in participants declaring past or chronic infection (Table 2). Other significant differences in health insurance plan, sexual activity and previous incarceration were also observed between self-reported HBV-status groups.

#### Previous HBV testing and vaccination

Participants reported having the following results from a previous HBV-test: negative, n = 835 (76.6%); effective vaccination, n = 181 (16.6%); past infection, n = 59 (5.4%); and chronic infection, n = 15 (1.4%). No one reported not knowing or remembering their test result. Previous tests were conducted as part of routine care (n = 586, 53.8%) or because the participant had an HBV-transmission risk-factor (n = 455, 41.7%), were about to receive HBV-vaccination (n = 21, 1.9%), donate blood (n = 14, 1.3%), or had abnormal liver enzymes or symptoms of liver-related illness (n = 14, 1.3%). Of those testing due to an HBV-transmission risk factor (n = 453 with available data), 397 (86.6%) had recent serological test result. Of the latter group, 100 (65.4%) were non-immunised, 173 (15.9%) had resolved infection (with median anti-HBs antibody level at 137 mIU/ml, IQR = 14–929) and 21 (1.9%) were HBsAg-positive. In Table 2, self-reported history of HBV-vaccine status is compared with serological results. There were 717 (65.8%) participants whose self-report agreed with the study test, giving an unweighted κ = 0.42. Of note, an agreement based on only self-reported test results from the previous HBV-test was much poorer (Supplementary Table 2). When examining individual disease status groups (with self-report/serology, respectively), an agreement was similar between negative/non-immunised (κ = 0.37), effective vaccine/vaccinated (κ = 0.48), past infection/resolved infection (κ = 0.35) and chronic infection/HBsAg-positive (κ = 0.44).

#### Discordance in HBV-status and its determinants

Of the 426 participants with negative self-reported history, 208 (48.8%) had a discordant serological result. Of them, 74 (35.6%) were resolved infections (with median anti-HBs antibody level at 96 mIU/ml, IQR = 10–425), 128 (61.5%) vaccinated (with median antibody level at 439 mIU/ml, IQR = 52–1000) and six (2.9%) had HBsAg-positive serology. As shown in Table 4, higher odds of negative HBV-infection discordance were found in individuals from an intermediate endemic country (P = 0.04), had parents from, travelled to, or received care in a region of moderate/high HBV-prevalence (P < 0.001) or who had CMU as their health insurance. Lower odds were observed in those from a high HBV-prevalent country (P = 0.02) and with more than one-lifetime sexual partner (P = 0.01) (Table 4). No multivariable analysis was conducted due to strong collinearity between variables, notably region of endemicity.

Of the 599 participants with self-reported history indicating effective vaccine, 446 (74.5%) were verified to have been vaccinated (with median anti-HBs antibody level at 459 mIU/ml, IQR = 90–1000) and 153 (25.5%) had a discordant serological result. Of the latter group, 100 (65.4%) were non-immunised, 50 (32.7%) had resolved infections (with median anti-HBs antibody level at 344 mIU/ml, IQR = 60–1000) and three (2.0%) had HBsAg-positive serology. Determinants for discordance in vaccinated self-reported history were male gender (P = 0.004); increased age (P = 0.007); having parents from, travelling to, receiving care in, or originating from a region of intermediate/
high HBV-prevalence ($P < 0.001$); lacking any health insurance plan ($P < 0.001$); and previously incarcerated individuals ($P = 0.02$) (Table 4). Again, no multivariable analysis was conducted due to strong collinearity between variables.

Discordance for individuals declaring past infection was not common (16.4%), as was for the few participants declaring chronic infection (30.0%) (Table 3). The risk-factor analysis was precluded by the small patient sizes and low discordances in these self-report groups.

**Discussion**

In this study conducted in the Paris metropolitan region among mostly MSM and immigrants, we observed that almost one-third
of participants did not have a serological HBV-status corresponding to their past clinical description. Self-reporting is known to be an inaccurate reflection of vaccinated [14–17, 20, 21] and susceptible [14, 17, 22, 23] at-risk individuals. By asking questions on both vaccination and HBV testing practices, we build on these previous reports to encompass a slightly more extensive evaluation of self-reported HBV-disease status. These findings bear particular importance for screening campaigns aimed at individuals belonging to various HBV-transmission risk groups who have been previously tested.

With an estimated 38 HBsAg tests per 1000 habitants and a 0.8% HBsAg-positive seroprevalence [24], HBV-testing could be viewed as redundant for many individuals in France and perhaps other screening methods could reduce this inefficiency. One potential option could be determining HBV-status from previous patient information, while hypothetically, any person correctly identifying their status through self-reports would not need serological confirmation. The proportion of discordant results could then be viewed as the proportion of individuals in need of further testing. Data from our study would suggest that roughly half of the patients declaring negative HBV-status and a quarter of patients with other self-reported status would benefit from an HBV serological test. Improvement in reducing unnecessary tests could also be achieved by including information from patient medical charts [25], yet this might not be feasible for many at-risk groups, such as immigrant populations seeking care for the first time.

The group with the highest discordance was individuals with negative self-reported status, with most discordant participants having serological evidence of vaccination. In parallel, most discordant participants describing effective vaccine from their clinical history were in fact non-immunised. From the risk-factor analysis, the groups with discordant negative and vaccinated HBV-status were similar: mainly individuals linked to regions of intermediate/high HBV-prevalence and not under the national health insurance plan. Knowledge about HBV transmission factors are generally good in these patient groups compared with others [26], yet they have evidenced difficulties in differentiating between negative and immunised statuses [27]. Moreover, general practitioners in France sometimes have difficulty in correctly interpreting HBV serologic results [28], possibly leading to further confusion among these individuals. More fostered education on HBV-status by trained specialists has demonstrated success in increasing understanding of HBV disease in Hmong and Asian/Pacific Islanders in the USA [29, 30] and could be of use in this setting.

Other hypotheses could account for why individuals claiming to be vaccinated were, in fact, non-immunised or had resolved the infection. First, anti-HBs antibodies are known to wane many years after vaccination for most individuals [31] and those without antibodies could have indeed been vaccinated at a younger age but lost antibodies at the time of participating in the study. It might explain why higher age was significantly associated with discordant ‘effective vaccine’ status. However, almost 90% reported receiving the vaccination during adolescence or adulthood and in light of the antibody levels detected in this group, the last vaccine booster could have been administered within the past decade [32]. Second, inadequate vaccine response is observed in 5% of immunocompetent individuals and is more frequent in other populations (i.e. older individuals, renal insufficiency, immunocompromised, etc.) [33]. Individuals could have in fact been vaccinated but failed to achieve an appropriate response. Finally, 8% of individuals claimed to be vaccinated, yet in fact, had resolved infection. These individuals could have had resolved infection prior to vaccination, while either no pre-vaccine screening had taken place or only anti-HBs and not anti-HBc antibodies were tested. Vaccination might not be effective for this patient profile [34].

Other studies have shown that self-reports of vaccine history are poor indicators of true immunised status in mostly IDUs, MSM and younger populations seeking STD screening, with predictive sensitivities ranging from 24 to 55% [14, 16, 17]. In contrast, we observed a much higher sensitivity, with an overall 86% correctly identifying their vaccinated status, which was even higher in the at-risk groups mentioned above (i.e. IDUs, MSM). The reasons for these discrepancies are difficult to explain. Compared with others, our study population had a much higher representation of lower risk groups with regular healthcare, for whom HBV-vaccination declaration could be more accurate. However, the research supporting this claim, wherein the sensitivities of vaccinated self-reports are compared between various risk-factors groups, is almost non-existent (apart from the one report demonstrating no difference in sensitivity among IDUs vs. non-IDUs [21]).

Importantly, the only discordance of participants reporting chronic infection was among those who in fact had resolved infection, whereas the most frequent serological status of discordant participants reporting past infection had HBsAg-positive

Table 3. Self-reported HBV-infection status compared with serological results

| Serological HBV-statusa | Self-reported statusb | Negative (n = 426) | Effective vaccine (n = 599) | Past infection (n = 55) | Chronic infection (n = 10) |
|-------------------------|----------------------|------------------|---------------------------|-----------------------|--------------------------|
| Non-immunised           |                      | 218 (51.2)       | 100 (16.7)                | 2 (3.6)               | 0 (0)                    |
| Vaccinated              |                      | 128 (30.1)       | 446 (74.5)                | 2 (3.6)               | 0 (0)                    |
| Resolved infection      |                      | 74 (17.4)        | 50 (8.4)                  | 46 (83.6)             | 3 (30.0)                 |
| HBsAg-positive          |                      | 6 (1.4)          | 3 (0.5)                   | 5 (9.1)               | 7 (70.0)                 |

Data from the Optiscreen-B study conducted from September 2010 to August 2011 in Paris, France among individuals reporting having been tested for hepatitis B virus (HBV).

aDisease status was defined according to serological results (given in Table 1).

bSelf-report was based on responses to the following questions: ‘Have you already been vaccinated against hepatitis B?’ and ‘What was the result of [your last] HBV test?’ Status was defined as follows: any individual who claimed HBV vaccination prior to participation was classified as belonging to the ‘effective vaccine’ group; all other individuals were then categorised in groups corresponding to their previous HBV-test result.
serology. HBsAg-negative participants assuming to have a chronic infection would have received unnecessary follow-up with a negligible risk of liver-related morbidity and thus the clinical ramifications would be considered minimal. In contrast, HBsAg-positive participants assuming to have past infection, even negative infection or vaccinated status, could lack appropriate care, progress to later stages of disease without treatment and continue transmitting HBV to others. Testing or re-testing these individuals, however, does not guarantee that they will be linked-to-care [35, 36], regardless of patient-oriented assistance [37] and the care received might not be fully adequate for viral hepatitis [38]. Taken together, these observations support the need for improved quality in the continuum-of-care for chronic hepatitis B.

For other discordant groups, the seriousness of their clinical outcomes in the absence of serological confirmation is debatable. Vaccinated participants whose self-reported clinical history coincides with a negative or past infection would require no further follow-up, except for possibly serological confirmation of protective immunity. Past-infected patients in whom negative or effective vaccination was reported might lack HBV-appropriate care. Risk of liver morbidity and mortality is exceedingly low in this patient

### Table 4. Determinants for discordant hepatitis B virus status

|                                | Negative (n = 426) | Effective vaccine (n = 599) |
|--------------------------------|-------------------|----------------------------|
|                                | OR (95% CI)       | P                      | OR (95% CI)       | P                      |
| Female vs male                 | 1.02 (0.69–1.50)  | 0.9                    | 0.55 (0.37–0.83)  | 0.004                  |
| Age (per 10 years)             | 1.03 (0.88–1.20)  | 0.7                    | 1.28 (1.07–1.54)  | 0.007                  |
| Parents from endemic region*   | 2.42 (1.57–3.74)  | <0.001                 | 4.17 (2.74–6.34)  | <0.001                 |
| Travelled to endemic region*   | 2.42 (1.57–3.74)  | <0.001                 | 4.53 (2.95–6.93)  | <0.001                 |
| Received care in endemic region* | 2.95 (1.80–4.84) | <0.001                 | 5.99 (3.59–10.00) | <0.001                 |
| Transfusion before 1992        | 1.86 (0.54–6.46)  | 0.3                    | 1.24 (0.48–3.21)  | 0.7                    |
| Acupuncture                    | 0.70 (0.41–1.20)  | 0.2                    | 1.03 (0.62–1.73)  | 0.9                    |
| Tattoos                        | 0.78 (0.47–1.30)  | 0.3                    | 1.50 (0.91–2.46)  | 0.11                   |
| Piercing                       | 1.17 (0.80–1.72)  | 0.4                    | 0.84 (0.57–1.24)  | 0.4                    |
| Close contact with HBV+ individual | 1.18 (0.61–2.26) | 0.6                    | 1.15 (0.65–2.02)  | 0.6                    |
| Men who have sex with men      | 1.33 (0.77–2.31)  | 0.3                    | 1.18 (0.75–1.84)  | 0.5                    |
| Nasal drug-use                 | 0.67 (0.40–1.13)  | 0.14                   | 0.69 (0.40–1.18)  | 0.18                   |
| Intravenous drug-use           | 0.35 (0.04–3.35)  | 0.4                    | 2.71 (1.80–9.14)  | 0.11                   |
| Long-term stay at a medical centre | 1.75 (0.71–4.31) | 0.2                    | 1.13 (0.39–3.21)  | 0.8                    |
| Previously incarcerated        | 0.62 (0.29–1.35)  | 0.2                    | 2.99 (1.17–7.60)  | 0.02                   |
| HBV-prevalence of birth region |                   |                        |                   |                        |
| Low (<2.0%)                    |                   |                        |                   |                        |
| Intermediate (2.0–8.0%)         | 2.51 (1.54–4.08)  | <0.001                 | 7.01 (4.18–11.75) | <0.001                 |
| High (>8.0%)                   | 0.51 (0.29–0.89)  | 0.02                   | 2.86 (1.75–4.68)  | <0.001                 |
| Health insurance plan          |                   |                        |                   |                        |
| Social security                | 1.00              |                        |                   |                        |
| CMU*                           | 2.69 (1.01–7.15)  | 0.048                  | 1.46 (0.57–3.77)  | 0.4                    |
| AME*                           | 1.46 (0.65–3.32)  | 0.4                    | 2.30 (0.55–9.51)  | 0.3                    |
| Other                          | 1.15 (0.16–8.26)  | 0.9                    | d                 |                        |
| None                           | 1.37 (0.68–2.75)  | 0.4                    | 6.02 (2.60–13.93) | <0.001                 |
| Nb of life-time sexual partners|                   |                        |                   |                        |
| 0–1                            | 1.00              |                        |                   |                        |
| 2–9                            | 0.40 (0.18–0.89)  | 0.03                   | 1.36 (0.55–3.39)  | 0.5                    |
| >10                            | 0.34 (0.16–0.75)  | 0.007                  | 0.84 (0.33–2.09)  | 0.7                    |
| >1 sexual partner within 12 mo.s | 1.13 (0.77–1.66) | 0.5                    | 0.84 (0.54–1.31)  | 0.4                    |

Data from the Optiscreen-B study conducted from September 2010 to August 2011 in Paris, France among individuals reporting having been tested for hepatitis B virus (HBV). Discordant defined as a self-report HBV-status that did not correspond to the participant’s serological test.

*Endemic defined as a region with moderate or high HBV prevalence. Travel period must have been longer than 3 months.

**Couverture médicale universelle**, health insurance coverage that is given to persons living in precarious situations (i.e. unemployed, poverty, etc.).

***Aide médicale d’état**, health insurance generally given to immigrants without proper documentation.

dParameter estimates were unable to be obtained.

For other discordant groups, the seriousness of their clinical outcomes in the absence of serological confirmation is debatable. Vaccinated participants whose self-reported clinical history coincides with a negative or past infection would require no further follow-up, except for possibly serological confirmation of protective immunity. Past-infected patients in whom negative or effective vaccination was reported might lack HBV-appropriate care. Risk of liver morbidity and mortality is exceedingly low in this patient...
group [39]; however, reactivation can occur under certain circumstances and might complicate clinical follow-up while undergoing anti-hepatitis C virus or immunosuppressive therapies [40]. Finally, any HBsAg-negative/anti-HBs antibody-negative individual reporting effective vaccination would unknowingly remain susceptible to infection. Vaccination after testing these individuals is paramount, yet uncommon in large campaigns such as ours [19].

Certain limitations of our study need to be addressed. First, we neither collected the date of past test nor did we ask questions on-at-risk HBV activities since the last test. It was then difficult to assess whether participants with self-reported negative status had discordance due to changing from negative to positive status during this period. Second, the study population only reflected individuals who were able to recall their HBV-test result. Including individuals unsure of their HBV-status or even without a previous test would evidently modify discordance results; however, they would require testing regardless of disease status based on self-reported patient history and thus irrelevant to the study question. Third, individuals were only asked if they had been vaccinated and not whether they had received enough vaccinations to provide adequate protection, which is implied by the definition of effective vaccine. We did ask participants the number of vaccines received and one-fifth of those with available data reported only one vaccine. Attempts were made to include this information when defining self-reported HBV status, yet these did not increase classification agreement or concordance (data not shown). Finally, we did ask the date at which vaccination occurred. As most participants only responded in categories of ‘at birth, adolescence, or adulthood’; the time since vaccination was difficult to fully assess.

In conclusion, HBV-status based on self-reported accounts of vaccination and previous testing is poor in confirming uninfected and to a lesser extent, vaccinated and infected individuals in this large screening study. These findings stress the need for serological testing to confirm and reinforce self-reports among at-risk individuals. For clinicians and public health workers, appropriately explaining HBV-status to individuals after testing bare considerable importance, especially for those from moderate to high HBV-endemic countries, in order to ensure appropriate care.

**Supplementary material.** The supplementary material for this article can be found at https://doi.org/10.1017/S0950268818002650.

**Acknowledgements.** We wish to thank all study participants as well as all medical and paramedical centres participating in the study and our data management centre, especially Frédéric Chau, Frédéric Potre, Isabelle Goderel and Grégory Pannetier. We also acknowledge Samia Hicham, Judith Leblanc, Manuela Sébire-Le Cam and Farid Djoumad for their extraordinary effort in data collection at various sites.

This work was supported by the Agence Nationale de Recherche contre le Sida et les Hépatites (grant no 2010-334, 2010) and Mairie de Paris (2010). Other unrestricted grants were received by Gilead Sciences (2010) and Roche (2010). A post-doctoral fellowship from SIDACTION was awarded to A.B. (2014) for some of the work presented in this manuscript. None of the funders was involved in any part of the data collection, analysis and manuscript writing.

**Conflict of interest.** None.

**References**

1. Schweitzer A et al. (2015) Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* 386, 1546–1555.

2. Hatzakis A et al. (2011) The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. *Journal of Viral Hepatitis* 18(suppl. 1), 1–16.

3. Lamportico P, Maini M and Papatheodoridis G (2015) Optimal management of hepatitis B virus infection – EASL special conference. *Journal of Hepatology* 63, 1238–1253.

4. McMahon B et al. (2016) Hepatitis-Associated liver cancer: gaps and opportunities to improve care. *Journal of the National Cancer Institute* 108, div359.

5. World Health Organization. WHO/UNICEF estimates of national immunization coverage [Internet]. 2017. [cited 2018 Sept 2]. Available at http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.html

6. World Health Organization (2017) Guidelines on Hepatitis B and C Testing. Geneva, Switzerland: World Health Organization.

7. Spenatto N et al. (2013) Hepatitis B screening: who to target? A French sexually transmitted infection clinic experience. *Journal of Hepatology* 58, 690–697.

8. Veldhuijzen IK et al. (2012) Identification and treatment of chronic hepatitis B in Chinese migrants: results of a project offering on-site testing in Rotterdam, The Netherlands. *Journal of Hepatology* 57, 1171–1176.

9. Zhou K et al. (2016) Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. *Lancet Infectious Diseases* 16, 1409–1422.

10. Bottero J et al. (2013) Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. *Journal of Hepatology* 58, 473–478.

11. Pioche C et al. (2018) Dépistage des hépatites B et C en France en 2016, nouvelle édition de l’enquête LaboHep [Hepatitis B and C screening in France in 2016. The New edition of the LaboHep study]. *Bulletin épidémiologique hebdomadaire* 11, 188–195, French.

12. Bottero J et al. (2016) French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. *Liver International* 36, 1442–1449.

13. LeFevre ML (2014) U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 161, 58–66.

14. Topp L et al. (2009) Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: a review. *Drug & Alcohol Review* 28, 669–675.

15. Brouard C et al. (2017) Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011–2013. *Epidemiology & Infection* 145, 1259–1269.

16. Nielsen US et al. (2015) Hepatitis B infection and vaccination coverage in men who have sex with men consulting a Danish venereology clinical practice. *Infectious Diseases* 47, 517–522.

17. Pitasi MA et al. (2014) Hepatitis B virus (HBV) infection, immunity and susceptibility among men who have sex with men (MSM), Los Angeles County, USA. *AIDS & Behavior* 18(suppl. 3), 248–255.

18. Legoupil C et al. (2017) Out-of-Hospital screening for HIV, HBV, HCV and Syphilis in a vulnerable population, a public health challenge. *AIDS Care* 29, 686–688.

19. Boyd A et al. (2017) Testing for hepatitis B virus alone does not increase vaccine coverage in non-immunized persons. *World Journal of Gastroenterology* 23, 7037–7046.

20. de la Fuente L et al. (2007) Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy ‘don’t ask, draw a blood sample, vaccinate and try to schedule another visit.’ *Journal of Clinical Virology* 38(1), 87–90.

21. Kuo I et al. (2004) Poor validity of self-reported hepatitis B virus infection and vaccination status among young drug users. *Clinical Infections Diseases* 38, 587–590.

22. Thornton L et al. (2000) Comparison between self-reported hepatitis B, hepatitis C, and HIV antibody status and oral fluid assay results in Irish prisoners. *Communicable Disease and Public Health* 3, 253–255.

23. Origer A and Schmit J-C (2012) Prevalence of hepatitis B and C and HIV infections among problem drug users in Luxembourg: self-report versus serological evidence. *Journal of Epidemiology & Community Health* 66, 64–68.
24. Pioche C et al. Indicateurs régionaux de dépistage et de prévalence des hépatites B et C. France 2010–2012 [Regional indicators of testing and prevalence for hepatitis B and C France 2010–2012]. Institut Veille Sanitaire [Internet]. 2014. [cited 2018 Sept 2]. Available at http://www.invs.sante.fr. French.

25. Fishbein DB et al. (2006) Determining indications for adult vaccination: patient self-assessment, medical record, or both? Vaccine 24, 803–818.

26. Brouard C et al. (2013) Hepatitis B knowledge, perceptions and practices in the French general population: the room for improvement. BMC Public Health 13, 576.

27. Upadhyaya N et al. (2010) Chronic hepatitis B: perceptions in Asian American communities and diagnosis and management practices among primary care physicians. Postgraduate Medicine 122, 165–175.

28. Girard A et al. (2010) Analysis of medical prescribing practices for hepatitis B serology tests. Gastroentérologie clinique et biologique 34, 8–15.

29. Chen MS et al. (2013) Increasing hepatitis B screening for hmong adults: results from a randomized controlled community-based study. Cancer Epidemiology, Biomarkers & Prevention 22, 782–791.

30. Zacharias T et al. (2015) HBV outreach programs significantly increase knowledge and vaccination rates among Asian pacific islanders. Journal of Community Health 40, 619–624.

31. Bruce MG et al. (2016) Antibody levels and protection after hepatitis B vaccine results of a 30-year follow-up study and response to a booster dose. Journal of Infectious Diseases 214, 16–22.

32. Wilson JN et al. (2007) Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules. Vaccine 25, 3705–3712.

33. Walayat S et al. (2015) Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World Journal of Hepatology 7, 2503–2509.

34. Wang Q, Klenerman P and Semmo N (2017) Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterology & Hepatology 2, 123–134.

35. Bottero J et al. (2016) Effectiveness of hepatitis B rapid tests toward linkage-to-care: results of a randomized, multicenter study. European Journal of Gastroenterology & Hepatology 28, 633–639.

36. Bottero J et al. (2015) Simultaneous human immunodeficiency virus-hepatitis B-hepatitis C point-of-care tests improve outcomes in linkage-to-care: results of a randomized control trial in persons without healthcare coverage. Open Forum Infectious Diseases 2, ofv162.

37. Perumalswami PV et al. (2013) Hepatitis outreach network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. Journal of Hepatology 58, 890–897.

38. Tedder RS et al. (2013) The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. Clinical Infectious Diseases 56, 951–960.

39. European Association for the Study of the Liver (2017) European association for the study of the liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. Journal of Hepatology 67, 370–398.

40. Loomba R and Liang TJ (2017) Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 152, 1297–1309.